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Abbreviations
GTP

Guanosine Triphosphate

GDP

Guanosine Diphosphate

GAP

GTPase Activating Protein

RPC

Ruthenium Polypyridyl Complex

DP

([Ru(dip)2phen]Cl2)

DB

([Ru(dip)2bpy]Cl2)

PTX

Paclitaxel

MT(s)

Microtubule(s)

MSA(s)

Microtubule Stabilizing Agent(s)

MDA(s)

Microtubule Destabilizing Agent(s)

DMSO

Dimethyl Sulfoxide

FL

Fluorescence

ITC

Isothermal Titration Calorimetry

CD

Circular Dichroism
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Abstract
Microtubules are cytoskeletal filaments that play a role in essential functions within the
cell such as cell motility, intracellular transport, structural support and chromosome segregation.
Tubulin is a heterodimeric protein that exhibits GTP dependent polymerization and selfassembles into polar microtubule filaments. Microtubules are dynamic polymers corresponding to
their role in separation of duplicated chromosomes during mitosis. As the polymers cycle through
rounds of polymerization and depolymerization based on their nucleotide state, the chromosomes
are pulled towards the poles in the mitotic cell. Their normal function and dynamics can be
disrupted in highly proliferative cells that interrupt cell cycle progression revealing microtubules
as an antimitotic cancer therapy target protein. Paclitaxel, also known as Taxol, is a current
chemotherapeutic agent that binds microtubules and stabilizes the polymerized state, disrupting
their dynamic action, stalling the cell cycle, and leading to apoptosis. Ruthenium-Polypyridyl
Complexes are metalloorganic compounds with aromatic ring structures complexed to a center
Ruthenium cation, some of which have been identified as a Microtubule Stabilizing Agent
(MSA). The novel RPCs under investigation in this research are ([Ru(dip)2bpy]Cl2) (DB) and
([Ru(dip)2phen]Cl2 (DP). The first goal of this research was to determine if these novel
compounds bind to microtubules. Fluorescence titrations between the microtubules and each
small molecule were performed with increasing concentration of the RPC to measure the binding
affinity (Kd). Polymerization data reveals that each novel small molecule enhances the rate and
degree of polymerization in a similar manner as Paclitaxel. Circular Dichroism reveals the
binding of the novel small molecule to MTs does not result in any significant secondary structural
changes. ITC data further supports the notion that the novel RPCs are tightly binding to MTs and
binding to a similar degree as other known MSAs, showing the importance in futher research
endeavors on these novel RPCs to determine their potential in antimitotic chemotherapy.
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Introduction
Microtubules are a primary component in cytoskeletal structures and play diverse
roles throughout the cell. Microtubules are formed by parallel arrangements of multiple
protofilaments that are repeated units of Tubulin (1). Tubulin is a heterodimeric protein
that consists of an α and β subunit, 55kDa each, exhibiting highly conserved sequence
homology. The polymerization of tubulin dimers is dependent on their guanine nucleotide
state with binding sites on each subunit. The α subunit contains the non-exchangeable site
(N site), while the β subunit contains the exchangeable site (E site) shown in Figure 1 (1,
2).

Figure 1. Heterodimer structure within Protofilament (2)

The N-site on α-tubulin is constitutively bound to GTP. Polymerization can
spontaneously occur if the E site on Tubulin is also bound to GTP, and optimally occurs
at 37oC. The growth phase is ensured by GTP caps at the ends of the protofilaments (1).
The tubulin-GTP conformation allows a straight, parallel arrangement of the
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protofilaments and creates a stable interaction (1). The GTP can be lost in the E site due
to the β subunit intrinsic GTPase activity (3). This hydrolyzing activity is activated once
the dimer has been added to the polymer, so the interior dimers will be GDP-tubulin
while the GTP protective caps determine the ultimate fate of the polymer (4). When this
protective GTP cap is lost at the β subunit end, a catastrophe event results, and the
microtubules enter a state of depolymerization. The intrinsic GTPase activity is almost
completely absent alone but can be potentiated by most notably Gαs, which is a GTPase
Activating Protein (GAP) for β-Tubulin (3). The α subunit of a GS-protein is GTP
activated during G-Protein Couple Receptor signaling and is involved in various signal
transduction cascades (5). Therefore, the microtubule structure is coordinated with many
events occurring in the cell with variability during certain periods for the cell.
The cyclical patterns of growth and shrinkage are shown in Figure 2. When
tubulin contains GTP bound in both subunits, the MTs will spontaneously enter a rescue
phase and increase in length by the addition of these GTP-Tubulin dimers (Figure 2).
When the GTP is lost from the regulatory β subunit at the protective end, the MTs will
enter catastrophe and depolymerize starting at that site (Figure 2).
Figure 2. Guanine-Nucleotide State dependent mechanism of MT Polymerization (4)
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The spontaneous dynamic activity of these polymers corresponds to their vital
role in the cell, especially in mitotic events (6). During interphase, the microtubules are
relatively stable with a low occurrence of catastrophe events (1). As a cell enters mitosis,
the microtubules are more unstable and experiencing higher dynamic periods of
shrinkage (1). Microtubules are organized in the centrosome and form the spindle
apparatus, creating a cytoskeletal attachment from the duplicated chromosomes to the
poles of the multiplying cell. As the microtubules cycle through these dynamic
catastrophic events, the chromatids are directionally pulled to separate poles of the cell
(6). Microtubules thus have an essential role in the mitotic pathway, providing a protein
target for therapies treating highly proliferative cellular pathologies.
Microtubules have specific domains that small molecules can bind and interfere
with normal MT function (Figure 3) (7-9). These drugs largely disrupt the equilibrium
between free tubulin dimers and microtubules (8,10). Four regions on the microtubules
have been well-characterized which include the taxoid, laulimalide, colchicine, and vinca
site (8,11). All of these drug targeting locations are found on the regulatory β subunit or
between the subunit interfaces.
Figure 3. Known Binding Domains in Microtubules (8)
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Microtubule targeting molecules can be categorized into two subsets: 1)
stabilizing and 2) destabilizing (12). Microtubule stabilizing agents, MSAs, bind to the
microtubules and stabilize the polymer. The microtubule destabilizing agents, MDAs,
bind to microtubules and increase the likelihood of depolymerizing catastrophic events
(12). These protein-drug interactions disrupt the normal dynamic activity of the
microtubules. A very important MSA is Paclitaxel, which is a current antineoplastic drug
used in the treatment of breast cancer and many advanced carcinoma’s (13). Paclitaxel
interacts with MTs and disrupts their normal activity during mitosis and most commonly
stalls the cell cycle at the M-phase checkpoint (13). This halt in cell cycle progression can
be from abnormal MT length or tension in the spindles due to the drug interaction and
interference with the normal MT dynamics (13). Cell cycle regulators precisely monitor
the progress of mitosis and arresting at the M-phase checkpoint can trigger an internal
cascade leading to apoptosis (10). This abnormal mitotic exit is an essential component
for an MSA to trigger apoptosis (14). The induction of apoptosis is a clear mechanism for
the suppression of oncogenic proliferation and tumorigenesis.
Microtubule Stabilizing Agents are complex organic molecules with many ring
structures and chiral centers (7). RPCs are Ruthenium Polypyridyl Complexes which
exhibit this aromatic property and are under evaluation for their activity as an MSA.
Ruthenium based compounds have largely gained interest due to their potency, low
toxicity, high efficacy and less overall drug resistance in comparison to more commonly
used metalloorganic antitumor drugs containing Platinum (15). RPC structural subtypes,
tris-chelate compounds, have been extensively investigated as they exhibit exceptional
chemical stability and are kinetically inert molecules (7). They also have been identified
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as metabolically stable from excretional studies in animal models (7). RPC tris-chelate
complexes’ strong chemical integrity is an important reason these compounds are being
investigated for potential therapeutics (7). Two tris-chelate compounds complexed with
Ruthenium, RPC1([Ru(phen)3]Cl2) and RPC2 ([Ru(DIP)3]Cl2), show in vitro
enhancement of polymerization and RPC2 in vivo strongly disrupts MT structure and
dynamics which further suggests the apoptotic pathway as the mechanism of its
cytotoxicity (7). Limitations with these small molecules is their requirement for organic
dissolution. Novel tris-chelate RPCs of particular interest to this research are DB
([Ru(dip)2bpy]Cl2) and DP ([Ru(dip)2phen]Cl2) (figure 4,5) which have been synthesized
in efforts to make more water-soluble in comparison to previously studied RPCs (7).

Figure 5. DP Molecular Structure
(unpublished data)

Figure 4. DB Molecular Structure
(unpublished data)

Of particular interest is the characterization of the binding interaction between
novel RPCs and MTs to futher understand the possible implications and effects of this
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interaction on intrinsic properties and dynamics of MTs. This research will investigate
whether the novel RPCs (DP and DB) bind to MTs by performing fluorescence binding
studies. The thermodynamics of such binding will be characterized using ITC. The
interaction will be further evaluated by a polymerization assay to determine whether DP
and DB act as an MSA through measuring the kinetics and degree of polymerization in
the presence and absence of the molecules. The secondary structure of the tubulin will be
evaluated for effects of the small molecules on these intrinsic properties of the protein.
The characterization of these parameters will allow for comparison of the novel small
molecules with others Ruthenium-Polypyridyl Complexes and Paclitaxel on the mode
and degree of impact on MTs which will add to our current working knowledge and
guide future research trajectories for their evaluation as an antimitotic chemotherapeutic
agent.
Materials and Methods
Reagents DB (Ru(dip)2bpy]Cl2) and DP ([Ru(dip)2phen]Cl2) were synthesized
and provided to the laboratory in a collaborative research effort from the University of
Texas. Tubulin porcine brain (>99%), GTP stock (100uM), general tubulin buffer (80mM
Piperazine-N-N’-bis[2-ethanesulfonic acid] sequisodium salt; 2.0mM Magnesium
chloride; 0.5mM Ethylene glycol-bis (b-amino-ethyl ether) N,N,N,N’-tetra-acetic acid,
pH 6.9), 60% glycerol tubulin buffer (general tubulin buffer + 60% v/v glycerol), DMSO
and Paclitaxel (10uM) were purchase from Cytoskeleton Inc. in the Tubulin
Polymerization Kit.
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Preparation of Aqueous RPC solutions Solubility studies completed show the
novel RPCs (DP and DB) are water soluble and soluble up to concentrated stocks of
10mM. The dissolution in water was enhanced by the addition of 50oC hot water bath for
2 min. DB and DP were also soluble to the same degree in 10% glycerol tubulin buffer.
10mM stocks were made in the 10% glycerol tubulin buffer to maintain solvent
consistency throughout experimentation and stored at -20oC.
Reconstitution of Tubulin For the first set samples, 3mg/mL (~55uM per
subunit) tubulin stocks were made using 10% glycerol tubulin buffer (1x6 dilution using
60% glycerol and general tubulin buffer) with a final GTP concentration of 1mM. 10mg
of lyophilized tubulin was added to 3.3 mL of 10% glycerol tubulin buffer + GTP
(1mM). The stocks were aliquoted in 100uL samples and immediately snap frozen in
liquid nitrogen and stored at -80oC. For the second set of samples, 10mg/mL (~180uM
per subunit) tubulin stocks were made using the same 10% glycerol tubulin buffer with a
final GTP concentration of 1mM. 10mg of tubulin was added to 1mL of the tubulin
buffer + GTP and 5 x 200uL samples were aliquoted, snap frozen and stored at -80oC.
Fluorescence Titrations Intrinsic tryptophan fluorescence spectroscopy was used
as tubulin contains 8 trp residues, therefore the fluorescence quenching can be observed
over the 300-400nm range with excitation at 280nm to observe the protein drug
interaction. 3mg/mL tubulin stocks were diluted in a 1x10 dilution using 900uL of 10%
glycerol tubulin buffer + GTP (1mM) and 100uL of the 3mg/mL stock giving a final
concentration of the dimer as 10mM. The small molecule concentration was optimized by
running initial scans starting with 5uL injection of 1mM drug or 0.5mM drug to 400uL of
10uM MT. The fluorescence readout gave a more consistent pattern and curve using the
9

1mM RPC sample and was chosen for the titration studies. A JASCO J-1500 CD
Spectrometer machine was used. The cell and holder temperature were set to 370C to
maintain the protein predominantly in the polymer form. The small molecule was titrated
into the 400uL of MT by 5uL injections manually (x10) and the fluorescence readout was
recorded after each injection. Each small molecule was run in a triplicate series. The Fmax
is 330nm for tryptophan, thus the fluorescence absorbance was reported at this
wavelength over an increasing concentration of the small molecule. The triplicates were
averaged and normalized using (F0-F)/F0. The data was fit to the Hill Plot using the
Origins software to report the Kd, or binding affinity.
Polymerization Assay The protocol was replicated from the manufacturers
instruction for the Optical Density based polymerization assay (Cytoskeleton BK006P)
and a BioTek Synergy H1 Hybrid reader was used for the study. Paclitaxel, provided in
the kit, was reconstituted using 100uL of DMSO, aliquoted and frozen in -80oC. The
assay was temperature regulated and performed at 37oC to maintain the protein in
polymer form, reducing temperature effects on polymerization rates. The 96-well plate
was pre-warmed in 37oC for 30 minutes prior to assay. 10uL of room temperature DP,
DB and PTX stocks were added in sets of three to the pre-warmed wells for a final
concentration of 10uM for each molecule. The 10mg/mL stock of tubulin was thawed
quickly by removal from -80oC into a 1-minute water bath at room temperature and put
immediately on ice. 400uL of 10mg/mL tubulin stock was diluted to 3mg/mL by the
addition of 840uL of ice cold 10% glycerol + GTP buffer. With a separate 96-well plate
on ice, 12 samples of 100uL (3mg/mL) of tubulin were aliquoted. A multi-channel
pipettor was used to transfer the 100ul x 12 samples to the pre-warmed well plate with
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well identities as follows: 3 MT, 3 MT + PTX, 3 MT + DP, 3 MT+ DB. Readings started
immediately. The spectrometer was set to kinetic mode with 61 cycles and 1 reading per
minute. The absorbance wavelength was set to 340nm and monochromatic light was
used. Data was normalized by subtracting the initial reading to control for any
absorbances due to the buffer or small molecules used. The curves were fit to the Hill
Plot using the Origins software to extract kinetic parameters such as Vmax.
Far-UV Circular Dichroism CD was performed on the JASCO J-1500 CD
Spectrometer at 37oC to investigate the secondary structural changes in the presence of
the small molecule. 50uL of the 10mg/mL tubulin stock was diluted to 0.5mg/mL by the
addition 950uL of 10% glycerol + GTP buffer. The 10% glycerol + GTP buffer used was
initially diluted 10x by the addition of water to minimize the concentration of salt in
solution. CD readings were taken over the range of 250nm to 190nm with a scan speed of
50nm/min. 5 readings were taken of 300uL of 0.5mg/mL MT at 37oC, averaged and
reported using Origins. 5 readings were taken of 300uL MT (0.5mg/mL) + 3uL small
molecule (10uM), averaged and reported using Origins. MT and small molecule were
incubated together on ice for 5 minutes before CD was started.
Isothermal Titration Calorimetry ITC was performed using a GE MicroCal
iTC200. The temperature was set to 37oC for preformed MT. 50uL of 10mg/mL tubulin
stock was diluted with 1.75mL of ice cold 10% glycerol buffer + GTP for a final
concentration of 10uM. The small molecule was prepped in a 1x100 dilution of the
10mM stock to 100uM in preparation for a 1x10 concentration difference between
protein and small molecule. 50uL of the molecule was titrated by 30 injections (1.66uL
each) into 300uL of MT (10uM) over 30 minutes. Blanks were completed before
11

experimental ITC to equilibrate and normalize. The data was analyzed in the Origins
software and provided thermodynamic parameters such as the binding constant (K),
enthalpy (ΔH), entropy (ΔS) and stoichiometric coefficient of binding (N).
Results
Tubulin Reconstitution
Tubulin was reconstituted with DI water, aliquoted and snap frozen in liquid
nitrogen and stored at -800C. Before experimentation, a 15% SDS-PAGE was performed
under reducing conditions. A strong band is visualized at 55kDa, the molecular weight of
each subunit. The concentration of tubulin run on the gel was 3mg/mL (~55uM per
subunit), with 35uL in each lane. Successful reconstitution is seen, without denaturation
occurring during storage time frame.

Figure 6. SDS-Page. Molecular weight marker Lane 1. Pure
Tubulin monomers visualized in lanes 2-5 at 55kDa.
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Novel-RPCs are water soluble
DP and DB were synthesized in efforts to make more water-soluble RPCs, which
proved successful. Each compound was initially dissolved in a hot water bath at 500C for
2 minutes with stirring, in 1mM concentrations. Specific to this research, these
compounds were soluble in the 10% glycerol tubulin buffer and soluble up to
concentrations of 10mM without the addition of heat, further proving the solubility of the
novel RPCs in hydrophillic solvents.
DP and DB addition to preformed MT exhibit a fluorescence redshift
The fluorescence readout was measured during the titration studies after each
addition of 5uL (x 10) of the small molecule to the preformed MT at 37oC. Fluorescence
quenching was observed which is a decrease in the intensity of FL emission (Figure 7,8)
that can be the result of energy transfer, molecular remodeling, or complex formation.
The results also show a fluorescence redshift which is a shift to longer wavelength, lower
intensity Fmax. This can be the result of the tryptophan amino acids in the dimer being
more exposed to the polar solvent, indicating some protein structural changes with the
addition of the small molecules.
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Figure 7. Fluorescence quenching observed for the interaction between MT and DP.
As the concentration of the small molecule increases, the FL signal decreases. The
Fmax of the first reading is approximately 330nm. The final reading with highest
concentration of the small molecule is around 345-350nm, indicating a redshift.
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Figure 8. Fluorescence quenching observed for the interaction between MT and DB.
As the concentration of the small molecule increases, the FL signal decreases. The
Fmax of the first reading is approximately 330nm. The final reading with highest
concentration of the small molecule is around 345-350nm, indicating a redshift.

14

DP and DB bind to preformed MTs with moderately strong binding affinities
DP and DB were evaluated for a possible binding interaction with preformed MT
using intrinsic tryptophan fluorescence titrations. The fluorescence was measured for a
constant concentration of the MT (10uM) and an increasing concentration of the small
molecule (0-110uM), by titrating a small amount and reading the FL readout after each
addition. The FL at the Fmax=330nm was reported for each triplicate, averaged and fit to
the Hill Plot (Figure 9,10). DP binds to MT with a Kd = 15uM. DB binds to MT with a
Kd=19uM. The hyperbolic curve and Kd in the micromolar range show the novel RPC
molecules are binding to the MT with a moderately strong binding affinity, which is in
agreement to previously studied non-soluble RPCs (7).
1.0
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Figure 9. Hill Plot binding Curve for DP + MT (37o C). Data was normalized using (Fo-F)/Fo. The FL
unit is reported at 330nm for an increasing concentration of the small molecule. A hyperbolic
curve and binding site saturation is visualized. The Kd=15uM which suggests a moderate to strong
binding affinity between DP and MT.
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Figure 10. Hill Plot binding Curve for DB + MT (37o C). Data was normalized using (Fo-F)/Fo. The FL unit is
reported at 330nm for an increasing concentration of the small molecule. A hyperbolic curve and binding
site saturation is visualized. The Kd=19uM which suggests a moderate to strong binding affinity between
DB and MT.

DP and DB acts as an MSA in vitro
The polymerization assay in vitro show the novel water-soluble RPCs enhance the
rate and degree of polymerization with comparison to the positive (MT + PTX) and
negative controls (MT) (Figure 11). The assay was performed at 37oC for preformed MT.
The Vmax for this experiment represents the maximal rate at which polymerization is
occurring. The MT + Paclitaxel with a Vmax=79mOD/min acts as the positive control as
Paclitaxel is a current MSA used in the treatment of cancer. The MT alone acts as the
negative control with a Vmax=22mOD/min. There is approximately a 3-fold enhancement
of the rate of polymerization in the presence of Paclitaxel supporting its identity as an
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MSA. DP was found to have a Vmax=43mOD/min, which is about a 2-fold increase in the
rate of polymerization, suggesting DP in vitro has microtubule-stabilizing properties. DB
was found to have a Vmax=56mOD/min which is 2.5 faster than the MT alone, suggesting
DB also has microtubule-stabilizing properties. The total OD corresponds to the length of
the polymer, which shows at saturation, these novel RPCs (DP and DB) also enhance the
degree of polymerization with respect to the MT alone, further suggesting their identify
as an MSA.
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Figure 11. Ligand binding effects on the polymerization of tubulin. Increase in turbidity (OD) is a
measure of polymer elongation. The rate of polymerization was measured in the assay over 60
minutes, in steady state 37oC. The positive control is (MT + PTX) which is a known MSA. The
negative control is (MT) which will show polymerization under experimental conditions but would
lack enhancement not in the presence of a small molecule. Novel-RPCs (DP and DB) show an
increase in the rate of polymerization (Vmax) and the degree of total polymerization at saturating
conditions (ODfinal). The novel small molecules show MSA properties in vitro.
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Secondary Structural effects on MT in the presence of DB and DP
Far-UV Circular Dichroism was used to qualitatively analyze the secondary
structure of the tubulin with and without the small molecules present. α-helices show a
large negative band at 220nm and β-sheets show a positive peak around 205nm. It has
been established through computation analyses using CD signals that Tubulin consists of
33% α-helices, 21% β-Sheets, and 45% random coils (16). The structural features are
seen in Figure 12, with a large negative peak around 220nm (α-helix) and a small positive
peak around 200-205nm (β-sheet). Small changes in the CD signal are seen with and
without the small molecule but suggests overall, there are no large structural changes
occurring when the MT is bound to DP (Figure 12).
Figure 12. Far-UV Circular Dichroism in the presence of the novel small
molecule show no large changes within the protein secondary structure
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Thermodynamics of DP binding to MT show similarities to other known RPCs
Isothermal titration calorimetry was completed to characterize the
thermodynamics of small molecule binding to preformed MTs (370C) by 50uL injections
of the water-soluble (100uM) small molecule into 300uL of (10uM) of MT. For
comparison, RPC2 (non-soluble MSA RPC) data has been reported in Table 1 (7).
Paclitaxel is known to bind to preformed MTs with a binding affinity (Kd) of 9.35E-8 M
(7). The binding affinity extracted from ITC isotherms for the novel small molecule is in
great correspondence with RPC2 and PTX and thermodynamic similarities between
RPC2 and DP would suggest these compounds exhibit similar modes of binding. A
stoichiometric coefficient (N) of 1.11 ± 0.003 was measured for the interaction between
DP and MTs, suggesting a 1:1 mole ratio for binding (Figure 13). This is in agreement
with other MSA/MDAs (docetaxel & RPC2 / colchicine) that also exhibit a N=1.
Isotherm data can be seen in Figure 13 for the DP + MT study.

Table 1. Thermodynamic properties of binding between MT and RPCs measured using ITC.

Complex
MT
MT

Ligand
DP
RPC2 (7)

Kd (uM)

ΔG (kcal/mol) ΔH(kcal/mol) -TΔS (kcal/mol)
0.6

-8.86

-14.6 ± 0.75

5.6

0.2

−9.1 ± 0.9

-16.6 ± 2.3

7.5
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Figure 13. ITC with preformed MT and DP. Isothermal inflection point shown
at approximately 1 (N).
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Discussion
Small molecules that target proteins with essential physiological functions have
been under investigation as a potential route for antitumor therapies, including
metalloorganic compounds. Platinum based compounds became the leading drug for
treating cancer with high efficacy, however there are reports of severe side effects of
bone marrow suppression and peripheral neuropathy thus there has been an initiative to
find novel metal-based compounds for cancer therapy (15). Research has revealed that
Ruthenium-based complexes show promising advantages over previously used Platinum
containing drugs regarding reduced drug resistance and lower toxicity (15). This research
has been focused on identifying Novel-RPCs that are more water-soluble and display
characteristic microtubule-stabilizing activity.
Novel RPCs, DP and DB, are water soluble compounds and soluble in
concentrations of 10mM. Ruthenium-based compounds have large aromatic ring
structures and have previously been known to have low solubility in aqueous systems and
with modification of the ligand structures (RPC1 and RPC2)(7), DB and DP show
remarkedly enhanced water-solubility. This development is significant progress in the
field of anticancer drugs as many are hydrophobic with strong limitations on the efficacy
and therapeutic safety (17). To enhance the solubility of these drugs, conjugation with
hydrophillic carriers has been a method to avoid this issue but this application is not
without consequences (17). The identification of DP and DB as water-soluble is a unique
feat for a possible anticancer drugs and would allow for increased bioavailability,
reducing the dose required for effective treatment and overall, reducing side effects and
increasing quality of life for a patient (17,18).
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Titrations with DP and DB to preformed MTs exhibits a fluorescence redshift, a
higher emission wavelength with increasing concentration, which supports the notion that
the novel molecules are interacting with the polymer. Exhibition of a redshift is indicative
of the tryptophan’s being more exposed to the hydrophillic solvent, indicating there are
molecular and structural changes in the MT occurring upon binding of the RPCs. These
molecular changes associated with fluorescence quenching can indicate complex
formation or energy transfer, which would be expected to occur if the novel molecules
bind the MTs. Research published in 2019 (7) was the first to characterize Ruthenium (II)
compounds interacting with MTs as their previous actions targeted DNA, mitochondria,
ER and different signaling pathways (15). Therefore, DP and DB are included in a small
subset of RPCs that have been recently identified as interacting with microtubules which
is a newly realized mode of action. Furthermore, no significant secondary structural
changes were seen in the dimer on CD spectra supporting the notion that overall
structural integrity is maintained even with DP binding.
DP and DB are binding to preformed MTs with a similar binding affinity as other
known MT interacting small molecules. Fluorescence data fit to a Hill Plot gave a
Kd=15uM for DP and Kd=19uM for DB which shows moderately strong binding to
preformed MTs. Preliminary ITC data for DP + MT gave a Kd=0.6uM, which is in strong
agreement with ITC data of MT+ RPC2 (7) with a Kd=0.2uM. This suggests that these
RPC compounds are binding with almost identical affinities. Reported Kd for Paclitaxel is
90nM (7) which is in exceptional agreement with the Kd’s for the novel water-soluble
RPCs (DP and DB), proving their importance in follow up work.
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The thermodynamics of binding reported from ITC suggest the non-soluble RPC2
and the novel water-soluble DP have similar modes of binding MTs due to very similar
magnitudes of Gibb’s Free Energy, enthalpy and entropy of binding. DP binds to
microtubules spontaneously through an exothermic process that results in more ordered
molecular products. This is in comparison to Paclitaxel with a reported ΔG=-41 kcal/mol,
ΔH=-57kcal/mol and -TΔS= 8.99 kcal/mol (19). Through competitive binding ITC, it has
been concluded that RPC2 binds to another region other than the taxane-binding domain
which is supported through the difference in magnitudes of the thermodynamics of
binding between RPC2 and Paclitaxel (7). This could possibly extend to our novel DP
since the thermodynamics are more similar to the RPC2, however this must be confirmed
with its own set of competitive binding experiments. The stoichiometric coefficient of
binding for DP to MT is N=1 and is consistent with all other known MSA/MDAs.
DP and DB act as a microtubule-stabilizing agent in vitro. The polymerization
assay shows an elevation in the Vmax and also the degree of polymerization/length of
polymer (total OD) for both small molecules. Paclitaxel is a current antineoplastic drug
that enhances the stability of microtubules and can induce apoptosis via mitotic arrest. In
my research, PTX acts as the positive control and shows 3-fold enhancement of the Vmax
of polymerization and degree of polymer formation. DP and DB novel molecules show
respectively 2 and 2.5-fold enhancement of the rate and degree of polymerization which
suggests their identity as an MSA. RPCs only recently were identified as interacting with
microtubules, such that DP and DB may be the first known water-soluble RutheniumPolypyridyl Complexes that act as an MSA.
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The preliminary characterization of novel water-soluble RPCs that bind, stabilize
and enhance polymerization with respect to microtubules is a promising feat in the
development of new cancer drugs. One of the biggest barriers to cancer therapy success is
the progression of drug resistance. Proposed methods of overcoming such resistance
includes developing novel drugs, combinations of drugs with different modes of actions
and improved pharmalogical targeting (deeper response, bioavailability) (20). The novel
RPCs (DP and DB) touch on aspects of all those notions. RPCs targeting microtubules
has been a new development in the last few years and our data shows a strong interaction
and stabilization effects. The MSA activity of DB and DP can be expected to follow such
a mechanism in vivo via the apoptotic pathway such as Paclitaxel (MSA). Furthermore,
the hydrophillic solubility is a positive feature for clinical applications and improved
penetrance in tissues. Future work can include competitive binding titrations with other
known MSA/MDAs to exclude/include known binding sites as a possible location for the
interaction between DP and DB with MTs. This can also be evaluated using
computerized binding simulations. Tumor microenvironments have a lower pH and
therefore a pH denaturation experiment would also be another avenue to consider.
Overall, there are many positive properties these novel RPCs exhibit when thinking of
tumorigenic applications and should be further investigated with their role in future
clinical treatment.
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